Key points are not available for this paper at this time.
Introduction: Primary central nervous system lymphoma (PCNSL) is a rare extranodal type of non-Hodgkin's lymphoma. Diffuse large B cell lymphoma (DLBCL) is most often histopathologically confirmed. Modern PCNSL therapy should include an induction and a consolidation phase. Treatment regimens are based on high doses of methotrexate, and the intensity of therapy is adapted to the age of patients and their biological condition. Material and methods: The aim of this study was a retrospective analysis of the effectiveness and toxicity of therapy used in patients diagnosed with DLBCL of the central nervous system (CNS), treated at the Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation in Wroclaw, Poland, between 2015 and 2022. The analyzed population included 46 patients with a median age of 64.5 years (range: 27–80). Patients were treated according to the R-MATRix, R-MPV, or R-HD-MTX-ARA-C regimen. Results: After the first-line treatment, complete remission (CR) was achieved in 11 patients, partial remission (PR) in 15, and seven did not respond to the therapy. 11 patients died and two were not qualified for chemotherapy due to their poor general condition. The effectiveness of R-MATRix and R-MPV was similar. Conclusions: We have shown that the use of the MATRix regimen is associated with greater toxicity and prolonged neutropenia.
Rybka et al. (Wed,) studied this question.